High SHIP2 expression indicates poor survival in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• SHIP2 (SH2-containing inositol 5 -phosphatase 2) regulates key cellular processes including insulin signaling and receptor endocytosis.
• SHIP2 has been implicated in tumor development and progression, but its specific role in colorectal cancer (CRC) remains unclear.
• Evaluating SHIP2's clinicopathologic significance in CRC is crucial for understanding its potential as a biomarker.

Purpose of the Study:

• To investigate the expression levels of SHIP2 in colorectal cancer (CRC) tissues.
• To determine the association between SHIP2 expression and clinicopathologic features in CRC patients.
• To evaluate SHIP2 as a potential prognostic marker for CRC.

Main Methods:

• Quantitative real-time polymerase chain reaction (qPCR) to assess SHIP2 mRNA expression.
• Immunohistochemistry (IHC) analysis on CRC tissue microarrays (TMA) to evaluate SHIP2 protein expression.
• Statistical analyses including Kaplan-Meier and Cox multifactor analysis to correlate SHIP2 expression with clinical outcomes.

Main Results:

• SHIP2 mRNA and protein expression were significantly higher in CRC tissues compared to noncancerous tissues (P < 0.05).
• SHIP2 protein levels were significantly associated with lymph node metastasis (P = 0.036), distant metastasis (P = 0.001), and overall survival (P = 0.009).
• High SHIP2 protein levels and positive distant metastasis were independently associated with unfavorable survival in CRC patients (P = 0.040 and P = 0.048, respectively).

Conclusions:

• SHIP2 is upregulated in colorectal cancer and serves as a significant prognostic indicator.
• SHIP2 expression levels correlate with advanced disease features and poorer patient survival.
• Targeting SHIP2 may represent a novel therapeutic strategy for colorectal cancer treatment.